Navigation Links
UT scientists discover link between protein and lung disease
Date:9/15/2009

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD). Findings appear online and will be in the January 2010 print issue of The FASEB Journal, the journal of The Federation of American Societies for Experimental Biology.

More than 12 million Americans are currently diagnosed with this incurable illness, which is the fourth leading cause of death, the National Heart Lung and Blood Institute reports. In the United States, the term COPD includes two main conditions - emphysema and chronic obstructive bronchitis.

The researchers were able to prevent COPD features in a mouse model by genetically removing osteopontin. To gauge the applicability of their findings to humans, the investigators analyzed the airways of people with COPD and found elevated levels of the protein.

"This is an important crossover study," said Michael Blackburn, Ph.D., the study's senior author and professor in the Department of Biochemistry and Molecular Biology at The University of Texas Medical School at Houston. "Because we can show osteopontin is elevated in people with COPD, this suggests that osteopontin could serve as both an indicator of disease progression and a therapeutic target."

In the study, researchers induced COPD features in mice and then compared symptoms experienced by mice with osteopontin and those without. The mice without the protein had less inflammation and lung disease. "The lack of osteopontin in the mice prevented the COPD features," said Daniel Schneider, the study's lead author and an M.D./Ph.D. candidate at the UT Health Science Center at Houston.

"This paper reveals exciting new information on the pathogenetic mechanisms involved in the development of chronic obstructive pulmonary disease and emphysema," said Richard J. Castriotta, M.D., professor and director of the Pulmonary, Critical Care and Sleep Medicine Division at the UT Medical School at Houston and medical director of the Sleep Disorder Center at Memorial Hermann - Texas Medical Center.

The study stems from research in Blackburn's laboratory involving a signaling molecule named adenosine, which can orchestrate the process of inflammation in wound healing. Adenosine can also activate a cell surface receptor associated with COPD named A2B and produce osteopontin.

Blackburn's decade-long research has focused on blocking the A2B receptor. With the new study linking osteopontin to COPD, Blackburn believes his laboratory may have uncovered a protein that could lead to a more targeted approach to treating emphysema.

"As a physician scientist, one goal of drug development is to offer more specific drug targets to treat the disorder and osteopontin provides a specific target that may be associated with fewer side effects," Schneider said.

"This paper adds a new element, osteopontin, to the mix by discovering its significant role in the development of COPD with emphysema ... It's still too early to be used clinically, but there may be a place for osteopontin in the future as an indicator of lung disease in progress that leads to COPD and emphysema," Castriotta said.


'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related biology news :

1. Alert status area in brain discoved by Hebrew University scientists
2. Master gene that switches on disease-fighting cells identified by scientists
3. Scientists seek new emphases in Arctic climate change research
4. Superscanner helps scientists see into the unknown
5. Scientists use microRNAs to track evolutionary history for first time
6. Michigan Tech scientists identify genes linked to Lou Gehrigs disease
7. Scientists discover new genetic variation that contributes to diabetes
8. Einstein scientists move closer to a safer anthrax vaccine
9. Scientists begin to untangle root cause of Alzheimers disease
10. NOAA scientists map fish habitat and movements at Grays Reef Marine Sanctuary
11. Scientists study possible responses to climate emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT scientists discover link between protein and lung disease
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
Breaking Biology Technology: